Skip to main content
. 2022 Aug 10;17(8):e0272364. doi: 10.1371/journal.pone.0272364

Fig 1. Discovery of anti-SARS-CoV-2 Spike RBD nanobodies that block interactions with ACE2.

Fig 1

(A) Construction of a synthetic humanized llama nanobody library. (B) Selection strategy for identification of anti-RBD nanobodies using phage panning. (C) Bio-layer interferometry binding profiles of RBD-1-1E, RBD-2-1F and RBD-1-2G against RBD-mFc (200 nM to 12.5 nM, 1:2 dilution). (D) Association (kon) and dissociation (koff) rate constants and equilibrium dissociation constants (KD) of nanobodies binding to RBD-mFc and S1-hFc. Global fit calculations for RBD-1-1E, RBD-2-1F, and RBD-1-2G used (200 nM to 12.5 nM), with all others using 200 nM to 50 nM. (E) Nanobodies inhibition of RBD-Fc binding to ACE2-Avi using AlphaLISA.